Mastura Md Yusof

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · Journal of Clinical Oncology · 2020 · 185 citations

Medicine, Oncology, Pharmacology +17

Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews

Caryn Mei Hsien Chan, Wan Azman Wan Ahmad, Mastura Md Yusof et al. · Psycho-Oncology · 2014 · 93 citations

Medicine, Oncology, Psychiatry +17

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · Annals of Oncology · 2021 · 52 citations · Full text

Medicine, Oncology, Pharmacotherapy +11